Biolinq
PrivateLast Round
Series C
Apr 22, 2025
Est. Valuation
$405M
Total Funding Raised
$214.75M
Company Overview
Biolinq operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series C round in April 2025.
Biolinq is a healthcare technology company that develops a wearable biosensor platform for continuous monitoring of metabolic health, including glucose, ketones, and lactate.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Health IoT, Sensors, Biotechnology
Business Model
B2C
Customer Profile
Hardware Sales, Hardware + Subscription
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Biolinq Comparables
Compare Biolinq with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| RSP Systems A/S | 84% | |
| HAGAR N.I.G. | 83% | |
| GlucoModicum | 82% |
For institutional investors. Book with your work email.
Biolinq Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Apr 22, 2025 | ||||
| VC Round | Apr 4, 2024 | ||||
| Series B | Nov 2, 2021 | ||||
| Series A Extension | Mar 28, 2019 | ||||
| Series A | Nov 27, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Biolinq Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Senvest Capital | Series B |
| Grey Sky Venture Partners | Series A |
| LifeSci Venture Partners | Series C, Series A, Series A Extension |
| Aphelion Capital | Series C, VC Round, Series B, Series A Extension |
| Able Partners | Series B |
| Senvest Management | VC Round, Series B |
| Longevity Vision Fund | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 28, 2026
Initial product is a Continuous Glucose Monitoring (CGM) sensor.
- Nov 1, 2025
Job posting discloses that Biolinq is a clinical stage medical device company, indicating its biosensor platform is undergoing clinical trials.
For institutional investors. Book with your work email.
Biolinq Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Biolinq's valuation, stock price, and market status.
Is Biolinq a public or private company?
Biolinq is a private company.
What is the current stock price of Biolinq?
Biolinq is a private company, so its shares have no public market price. Caplight tracks Biolinq's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Biolinq worth (valuation)?
Biolinq's valuation is estimated at $405.0M based on funding round data.
Can I buy Biolinq stock?
Biolinq shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Biolinq's last funding round?
Biolinq's most recent funding round was Series C on April 22, 2025.
Who are the main investors in Biolinq?
Key investors in Biolinq include LifeSci Venture Partners, Aphelion Capital, M Ventures, RiverVest Venture Partners, JDRF.
Will Biolinq IPO soon?
No public IPO plans have been announced for Biolinq.
How can I track Biolinq secondary market activity?
Caplight tracks bids, offers, and trades in Biolinq's shares on secondary markets.